Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells
- 9 May 2010
- journal article
- research article
- Published by Springer Nature in Acta Diabetologica
- Vol. 49 (S1) , 59-63
Abstract
Dipeptidyl peptidase 4 (DPP-4) is an enzyme that is produced by endothelial cells in different districts and circulates in plasma. Patients with type 2 diabetes show a reduction in active Glucagon-Like Peptide-1 (GLP-1) that could be due to impairment of secretion or its degradation or both. GLP-1 is rapidly inactivated in vivo, mainly by the DPP-4. Some authors suggest that Metformin has no direct inhibitory effect on DPP-4 activity and that Metformin and the other biguanides enhance GLP-1 secretion; others suggest a possible role of Metformin in the inhibition of the DPP-4 activity. In order to better elucidate the role of insulin sensitizers on the modulation of GLP-1 circulating levels, DPP-4 activity and mRNA expression were measured in cultured human aortic endothelial cells (HAEC) and human microvascular dermal endothelial cells (HMVEC) exposed to high glucose, Metformin and Rosiglitazone. Present data show that hyperglycemia is capable of increasing in a significant manner the DPP-4 activity only in microvascular endothelial cells. Rosiglitazone is able to modulate in a negative manner the expression of DPP-4 but not its activity in macrovascular endothelial cells, while at 24 h of exposure it is able to increase significantly DPP-4 activity but not its expression in microvascular endothelial cells. Metformin at 48 h only in microvascular endothelial cells is able to reduce in a significant manner (p = 0.01) the activity of DPP-4 but not its expression. The modulation of DPP-4 is site specific.Keywords
This publication has 19 references indexed in Scilit:
- Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1European Journal of Pharmacology, 2007
- Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1European Journal of Pharmacology, 2006
- Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitusDiabetologia, 2005
- Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetesDiabetic Medicine, 2005
- Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1Biochemical and Biophysical Research Communications, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Reference Values for Plasma Dipeptidyl Peptidase IV Activity and Their Association with Other Laboratory ParametersClinical Chemistry and Laboratory Medicine (CCLM), 2001
- ChemInform Abstract: The Unique Properties of Dipeptidyl-Peptidase IV (DPP IV / CD26) and the Therapeutic Potential of DPP IV InhibitorsChemInform, 1999
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEuropean Journal of Biochemistry, 1993
- A histochemical study by light and electron microscopy of the distribution of dipeptidyl peptidase-IV activity in the human dental pulpArchives of Oral Biology, 1992